MeSH term
Frequency | Condition_Probility | Acute Disease | 14 | 0.0 |
Adult | 59 | 0.0 |
Comparative Study | 75 | 0.0 |
Humans | 985 | 0.0 |
Animals | 450 | 0.0 |
Oligonucleotide Array Sequence Analysis | 22 | 2.0 |
Albumins/metabolism | 2 | 1.0 |
Albuminuria/*prevention & control | 2 | 2.0 |
Antihypertensive Agents/*therapeutic use | 2 | 0.0 |
Diabetes Mellitus, Type 2/complications/*drug therapy | 2 | 2.0 |
Hypertension/complications/*drug therapy | 2 | 1.0 |
Indoles/*therapeutic use | 2 | 1.0 |
Renin-Angiotensin System/*drug effects | 2 | 1.0 |
Aged | 44 | 0.0 |
Cardiac Output, Low/*mortality | 3 | 5.0 |
Coronary Arteriosclerosis/mortality | 3 | 5.0 |
Risk | 3 | 0.0 |
Surgical Procedures, Elective/*mortality | 3 | 5.0 |
Time Factors | 71 | 0.0 |
Aged, 80 and over | 16 | 0.0 |
Fatal Outcome | 2 | 0.0 |
Female | 118 | 0.0 |
Biopsy | 5 | 0.0 |
Blotting, Northern | 22 | 0.0 |
Breast Neoplasms/*genetics/metabolism/pathology | 2 | 3.0 |
Gene Expression Profiling | 11 | 1.0 |
*Gene Expression Regulation, Neoplastic | 20 | 1.0 |
Neoplasm Proteins/*genetics | 5 | 0.0 |
RNA, Messenger/genetics/metabolism | 18 | 0.0 |
Research Support, Non-U.S. Gov't | 714 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 46 | 0.0 |
Tumor Cells, Cultured | 303 | 1.0 |
Cell Division | 67 | 1.0 |
DNA-Binding Proteins/metabolism/*physiology | 15 | 12.0 |
Male | 126 | 0.0 |
Mice | 282 | 0.0 |
Mice, Nude | 15 | 0.0 |
Prostatic Neoplasms/metabolism/*pathology | 2 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 53 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 354 | 0.0 |
Trans-Activators/metabolism/*physiology | 12 | 20.0 |
Cytokines/pharmacology | 20 | 5.0 |
DNA-Binding Proteins/*metabolism | 249 | 12.0 |
In Vitro | 21 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 11 | 1.0 |
*Milk Proteins | 139 | 29.0 |
Mitogen-Activated Protein Kinases/*metabolism | 15 | 2.0 |
Signal Transduction | 221 | 3.0 |
Trans-Activators/*metabolism | 268 | 27.0 |
*Apoptosis | 16 | 1.0 |
Cell Survival | 18 | 1.0 |
Cyclins/metabolism | 4 | 0.0 |
DNA-Binding Proteins/*physiology | 50 | 9.0 |
Models, Biological | 43 | 1.0 |
Trans-Activators/*physiology | 58 | 22.0 |
Base Sequence | 112 | 0.0 |
DNA Primers | 27 | 0.0 |
Electrophoretic Mobility Shift Assay | 22 | 5.0 |
Tyrosine/*metabolism | 11 | 3.0 |
DNA-Binding Proteins/physiology | 24 | 8.0 |
Dose-Response Relationship, Drug | 49 | 0.0 |
Hela Cells | 22 | 0.0 |
Plasmids | 6 | 0.0 |
Promoter Regions (Genetics)/drug effects | 6 | 4.0 |
Receptors, Interleukin/genetics | 3 | 10.0 |
Trans-Activators/physiology | 21 | 15.0 |
Transcription, Genetic/*drug effects | 3 | 0.0 |
Cell Differentiation | 32 | 1.0 |
Cell Line | 210 | 1.0 |
Cells, Cultured | 153 | 0.0 |
Hematopoiesis | 5 | 2.0 |
Hematopoietic Stem Cells/*physiology | 2 | 1.0 |
Kinetics | 44 | 0.0 |
Mice, Inbred BALB C | 22 | 0.0 |
Mice, Inbred C57BL | 28 | 0.0 |
Mutation | 44 | 0.0 |
RNA, Messenger/biosynthesis | 19 | 1.0 |
Transduction, Genetic | 5 | 1.0 |
Blotting, Western | 96 | 1.0 |
Cell Movement | 6 | 0.0 |
DNA/metabolism | 66 | 4.0 |
DNA-Binding Proteins/metabolism | 168 | 8.0 |
Enzyme Activation | 85 | 2.0 |
Mitogen-Activated Protein Kinases/metabolism | 51 | 4.0 |
NF-kappa B/metabolism | 20 | 2.0 |
Phosphorylation | 327 | 4.0 |
Precipitin Tests | 51 | 1.0 |
Protein Binding | 74 | 0.0 |
Protein Kinases/*metabolism | 5 | 1.0 |
Protein-Tyrosine Kinase/metabolism | 77 | 8.0 |
Serine/metabolism | 16 | 5.0 |
Trans-Activation (Genetics) | 38 | 2.0 |
Tyrosine/metabolism | 98 | 8.0 |
p38 Mitogen-Activated Protein Kinases | 20 | 3.0 |
3T3 Cells/drug effects/metabolism | 2 | 16.0 |
Arsenicals/pharmacology | 3 | 14.0 |
Carrier Proteins/metabolism | 10 | 1.0 |
Endosomes/metabolism | 2 | 1.0 |
Epidermal Growth Factor/*pharmacology | 8 | 0.0 |
Genes, Reporter | 37 | 1.0 |
Membrane Proteins/metabolism | 3 | 0.0 |
Peptide Fragments/genetics/physiology | 2 | 15.0 |
Protein Processing, Post-Translational | 15 | 1.0 |
Receptor, Epidermal Growth Factor/physiology | 8 | 10.0 |
Recombinant Fusion Proteins/physiology | 7 | 2.0 |
Transfection | 184 | 1.0 |
Enzyme Activation/drug effects | 27 | 2.0 |
Interleukin-10/*pharmacology | 8 | 8.0 |
Interleukins/*pharmacology | 6 | 8.0 |
Protein-Tyrosine Kinase/*metabolism | 79 | 9.0 |
Proteins/metabolism | 38 | 4.0 |
*Proto-Oncogene Proteins | 111 | 6.0 |
Rats | 82 | 0.0 |
Signal Transduction/drug effects | 43 | 6.0 |
Alleles | 3 | 0.0 |
Apoptosis/genetics | 3 | 1.0 |
Disease Progression | 8 | 0.0 |
Mice, Knockout | 24 | 0.0 |
Mice, Transgenic | 17 | 0.0 |
Apoptosis | 39 | 2.0 |
Cyclins/physiology | 2 | 5.0 |
DNA-Binding Proteins/genetics/*metabolism | 64 | 6.0 |
Gene Deletion | 14 | 0.0 |
Genes, p53 | 2 | 0.0 |
Neoplasm Proteins/genetics/*metabolism | 2 | 1.0 |
*Nuclear Proteins | 3 | 0.0 |
*Protein Processing, Post-Translational | 3 | 1.0 |
*Protein-Serine-Threonine Kinases | 21 | 2.0 |
Trans-Activators/genetics/*metabolism | 61 | 16.0 |
*Transcription Factors | 41 | 2.0 |
DNA, Complementary/genetics | 7 | 0.0 |
DNA-Binding Proteins/analysis/*metabolism | 6 | 30.0 |
Down-Regulation | 26 | 1.0 |
Genes, Tumor Suppressor | 2 | 0.0 |
Papillomavirus, Human/*physiology | 2 | 10.0 |
Phosphotransferases/metabolism | 2 | 4.0 |
Phosphotyrosine | 10 | 3.0 |
Trans-Activators/analysis/*metabolism | 5 | 62.0 |
Binding Sites | 53 | 0.0 |
Carrier Proteins/physiology | 3 | 2.0 |
*Intracellular Signaling Peptides and Proteins | 34 | 4.0 |
Proteins/physiology | 4 | 2.0 |
*Repressor Proteins | 47 | 4.0 |
*Signal Transduction | 109 | 5.0 |
Cell Division/physiology | 15 | 1.0 |
Gene Expression Regulation, Neoplastic | 23 | 1.0 |
Immunohistochemistry | 33 | 0.0 |
Neoplasm Metastasis | 5 | 0.0 |
Neoplasm Staging | 5 | 0.0 |
Prognosis | 12 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 4 | 0.0 |
Trans-Activators/biosynthesis/genetics/*physiology | 2 | 13.0 |
Acute-Phase Proteins/metabolism | 17 | 26.0 |
Amino Acid Sequence | 64 | 0.0 |
Cell Death | 4 | 1.0 |
Cytokines/genetics | 3 | 2.0 |
Molecular Sequence Data | 124 | 0.0 |
Phosphotyrosine/analysis | 8 | 14.0 |
Transcription, Genetic | 57 | 1.0 |
Antigens, CD/metabolism | 25 | 2.0 |
Carcinoma, Hepatocellular/metabolism | 4 | 4.0 |
Cell Compartmentation | 3 | 0.0 |
Cell Membrane/metabolism | 10 | 0.0 |
Cytosol/metabolism | 8 | 1.0 |
Liver Neoplasms/metabolism | 3 | 4.0 |
Membrane Glycoproteins/metabolism | 26 | 4.0 |
Recombinant Proteins/metabolism/pharmacology | 7 | 6.0 |
Up-Regulation/genetics/immunology | 3 | 5.0 |
Breast Neoplasms/*pathology | 2 | 0.0 |
Cell Division/*drug effects | 4 | 1.0 |
DNA, Neoplasm/biosynthesis | 2 | 1.0 |
Leptin/*pharmacology | 9 | 30.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 22 | 5.0 |
Mitogen-Activated Protein Kinase 3 | 35 | 5.0 |
Recombinant Proteins/pharmacology | 25 | 1.0 |
Thymidine/metabolism | 4 | 1.0 |
Trans-Activators/metabolism | 178 | 19.0 |
*Gene Expression Regulation | 24 | 1.0 |
Interferon Type I/metabolism | 2 | 40.0 |
Proteins/genetics/metabolism | 6 | 3.0 |
Transcription Factors/*metabolism | 14 | 0.0 |
Carcinoma, Hepatocellular/*metabolism | 4 | 3.0 |
Cell Line, Tumor | 66 | 2.0 |
DNA-Binding Proteins/chemistry/*metabolism | 12 | 7.0 |
Trans-Activators/chemistry/*metabolism | 12 | 18.0 |
Staurosporine/*analogs & derivatives/*pharmacology | 2 | 25.0 |
Transformation, Genetic | 2 | 1.0 |
Translocation, Genetic | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Zinc Fingers | 4 | 0.0 |
*Dreams | 2 | 50.0 |
Infarction, Anterior Cerebral Artery/*complications/pathology | 2 | 50.0 |
Magnetic Resonance Imaging/methods | 2 | 2.0 |
*Occipital Lobe/pathology | 2 | 50.0 |
Polysomnography/methods | 2 | 40.0 |
Sleep Disorders/*etiology/pathology | 2 | 50.0 |
Sleep, REM/physiology | 2 | 11.0 |
Epithelial Cells/*drug effects/metabolism | 2 | 11.0 |
Interleukin-6/*pharmacology | 67 | 31.0 |
Luciferases/metabolism | 30 | 4.0 |
Promoter Regions (Genetics) | 54 | 1.0 |
RNA, Messenger/metabolism | 37 | 0.0 |
Transcription Factor AP-1/metabolism | 8 | 2.0 |
Interleukin-1/metabolism | 2 | 0.0 |
Interleukin-6/*metabolism | 20 | 19.0 |
*Promoter Regions (Genetics) | 14 | 0.0 |
Up-Regulation | 29 | 1.0 |
Dimerization | 43 | 3.0 |
Interleukin-12/pharmacology | 3 | 6.0 |
Receptors, Interleukin/*chemistry | 2 | 28.0 |
*Intercellular Signaling Peptides and Proteins | 2 | 0.0 |
Mitogen-Activated Protein Kinase Kinases/*metabolism | 3 | 5.0 |
Recombinant Fusion Proteins/pharmacology | 4 | 4.0 |
Umbilical Veins/cytology | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 63 | 2.0 |
Platelet-Derived Growth Factor/*pharmacology | 3 | 3.0 |
Reactive Oxygen Species/metabolism | 4 | 1.0 |
Signal Transduction/drug effects/*physiology | 9 | 4.0 |
src-Family Kinases/antagonists & inhibitors/metabolism | 2 | 15.0 |
Apoptosis/*drug effects | 16 | 2.0 |
Multiple Myeloma/*pathology | 7 | 11.0 |
*Transforming Growth Factor beta | 2 | 1.0 |
Cell Transformation, Neoplastic | 10 | 1.0 |
DNA-Binding Proteins/analysis/*biosynthesis | 2 | 16.0 |
Prostatic Neoplasms/*pathology | 12 | 10.0 |
Trans-Activators/analysis/*biosynthesis | 2 | 40.0 |
Antigens, CD/physiology | 10 | 4.0 |
Cell Survival/drug effects | 11 | 1.0 |
Drug Synergism | 18 | 1.0 |
Growth Substances/pharmacology | 2 | 1.0 |
Interleukin-6/physiology | 7 | 11.0 |
Membrane Glycoproteins/physiology | 10 | 6.0 |
Middle Aged | 46 | 0.0 |
Multiple Myeloma/genetics/*metabolism/pathology | 2 | 50.0 |
RNA, Neoplasm/biosynthesis | 5 | 3.0 |
Receptors, Interleukin/biosynthesis/genetics | 2 | 28.0 |
Tumor Necrosis Factor-alpha/pharmacology | 7 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Immunoprecipitation | 4 | 1.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/*metabolism | 4 | 7.0 |
Quinazolines/pharmacology | 5 | 6.0 |
Repressor Proteins/genetics/*metabolism | 3 | 1.0 |
Transcription Factors/genetics/*metabolism | 9 | 1.0 |
Case-Control Studies | 4 | 0.0 |
Child | 6 | 0.0 |
DNA-Binding Proteins/isolation & purification/*metabolism | 6 | 8.0 |
Trans-Activators/isolation & purification/*metabolism | 5 | 38.0 |
Transcription Factors/physiology | 5 | 2.0 |
3T3 Cells | 34 | 1.0 |
COS Cells | 33 | 1.0 |
Phosphotyrosine/metabolism | 30 | 7.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 3 | 1.0 |
Interleukin-2/metabolism | 2 | 1.0 |
Oncogene Proteins, Fusion/genetics/*metabolism | 2 | 5.0 |
Receptors, Interleukin-2/metabolism | 3 | 1.0 |
Response Elements/genetics | 6 | 3.0 |
Cell Line, Transformed | 18 | 1.0 |
DNA-Binding Proteins/antagonists & inhibitors/genetics/*metabolism | 5 | 22.0 |
Endothelial Growth Factors/genetics/*metabolism | 2 | 2.0 |
Mutagenesis, Site-Directed | 28 | 0.0 |
Neoplasm Transplantation | 7 | 0.0 |
*Neovascularization, Pathologic | 3 | 0.0 |
Promoter Regions (Genetics)/genetics | 16 | 1.0 |
Trans-Activators/antagonists & inhibitors/genetics/*metabolism | 6 | 42.0 |
Vascular Endothelial Growth Factor A | 7 | 0.0 |
Vascular Endothelial Growth Factors | 7 | 0.0 |
Annexin A5/metabolism | 2 | 2.0 |
Apoptosis/drug effects | 20 | 2.0 |
Carrier Proteins/genetics/metabolism | 4 | 2.0 |
Protein Transport | 8 | 1.0 |
Transforming Growth Factor beta/*pharmacology | 4 | 1.0 |
Tumor Cells, Cultured/drug effects/metabolism | 8 | 4.0 |
Epithelial Cells/*metabolism | 2 | 1.0 |
Genes, Dominant | 21 | 2.0 |
Immunoblotting | 20 | 0.0 |
Receptors, Interleukin-6/metabolism | 9 | 33.0 |
Cell Nucleus/*metabolism | 6 | 1.0 |
DNA, Neoplasm/*metabolism | 2 | 6.0 |
Fluorescent Antibody Technique | 8 | 0.0 |
Liver/enzymology | 3 | 0.0 |
Molecular Chaperones/metabolism | 3 | 6.0 |
Ultraviolet Rays | 5 | 0.0 |
DNA-Binding Proteins/genetics/*physiology | 10 | 4.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 9 | 4.0 |
Signal Transduction/*drug effects/physiology | 6 | 10.0 |
Trans-Activators/genetics/*physiology | 9 | 10.0 |
Protein Structure, Tertiary | 37 | 0.0 |
Signal Transduction/physiology | 26 | 2.0 |
src-Family Kinases/*metabolism | 5 | 3.0 |
Cell Differentiation/drug effects | 25 | 2.0 |
Cell Division/drug effects | 80 | 2.0 |
Phosphorylation/drug effects | 46 | 5.0 |
Breast Neoplasms/genetics/*pathology | 2 | 4.0 |
DNA-Binding Proteins/genetics/physiology | 4 | 5.0 |
Gene Expression | 33 | 0.0 |
Protein-Tyrosine Kinase/metabolism/physiology | 3 | 30.0 |
Trans-Activators/genetics/physiology | 3 | 11.0 |
Drug Interactions | 2 | 0.0 |
Drug Resistance | 5 | 0.0 |
Response Elements | 5 | 2.0 |
Retinoid X Receptors | 2 | 0.0 |
Transcription, Genetic/drug effects | 13 | 2.0 |
Tretinoin/pharmacology | 8 | 2.0 |
Cell Cycle/drug effects | 11 | 2.0 |
Cyclin D1/genetics | 2 | 3.0 |
Flow Cytometry | 24 | 0.0 |
Mitogen-Activated Protein Kinase 8 | 4 | 5.0 |
Proto-Oncogene Proteins/metabolism | 23 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 14 | 3.0 |
Receptor, Epidermal Growth Factor/metabolism | 10 | 1.0 |
DNA Primers/chemistry | 6 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 14 | 0.0 |
Flavonoids/pharmacology | 15 | 4.0 |
Mitogen-Activated Protein Kinase 1/*metabolism | 3 | 2.0 |
Polymerase Chain Reaction | 22 | 0.0 |
Gene Expression Regulation | 41 | 1.0 |
Histones/metabolism | 2 | 0.0 |
Interleukin-6/pharmacology | 35 | 12.0 |
Nuclear Proteins/*metabolism | 5 | 0.0 |
*Saccharomyces cerevisiae Proteins | 3 | 0.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 13 | 10.0 |
Leukemia, Myelocytic, Acute/*genetics | 3 | 2.0 |
Neoplasm Proteins/*metabolism | 11 | 2.0 |
Oncogene Proteins, Fusion/*metabolism | 2 | 10.0 |
*Translocation, Genetic | 3 | 0.0 |
Gene Expression/physiology | 6 | 1.0 |
Thrombin/*pharmacology | 6 | 5.0 |
Tissue Inhibitor of Metalloproteinase-1/genetics/*metabolism | 2 | 66.0 |
Mitogen-Activated Protein Kinases/physiology | 7 | 6.0 |
Phosphotyrosine/physiology | 2 | 20.0 |
K562 Cells | 4 | 0.0 |
Megakaryocytes/metabolism | 2 | 5.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors | 5 | 8.0 |
*Trans-Activation (Genetics) | 14 | 1.0 |
Tyrphostins/pharmacology | 24 | 16.0 |
Cell Cycle | 12 | 1.0 |
Epidermal Growth Factor/pharmacology | 12 | 1.0 |
Imidazoles/pharmacology | 5 | 2.0 |
MAP Kinase Signaling System/*physiology | 2 | 2.0 |
Pyridines/pharmacology | 5 | 1.0 |
Up-Regulation/*physiology | 2 | 4.0 |
Apoptosis/*drug effects/genetics | 3 | 9.0 |
Cell Division/drug effects/genetics | 5 | 5.0 |
DNA-Binding Proteins/*antagonists & inhibitors/genetics/metabolism | 4 | 50.0 |
Models, Molecular | 15 | 0.0 |
Structure-Activity Relationship | 20 | 0.0 |
Substrate Specificity | 8 | 0.0 |
Trans-Activators/*antagonists & inhibitors/genetics/metabolism | 4 | 50.0 |
Xenograft Model Antitumor Assays | 2 | 0.0 |
Antineoplastic Agents/pharmacology | 12 | 2.0 |
Cell Nucleus/metabolism | 59 | 3.0 |
Genistein/pharmacology | 4 | 3.0 |
Lipopolysaccharides/pharmacology | 10 | 1.0 |
DNA-Binding Proteins/*immunology | 2 | 8.0 |
Disease Models, Animal | 7 | 0.0 |
Interleukin-2/pharmacology | 8 | 1.0 |
Rabbits | 6 | 0.0 |
Signal Transduction/*immunology | 17 | 4.0 |
Trans-Activators/*immunology | 2 | 16.0 |
Cercopithecus aethiops | 11 | 0.0 |
Epithelial Cells/metabolism/virology | 2 | 28.0 |
Interleukin-6/*biosynthesis | 2 | 1.0 |
NF-kappa B/*metabolism | 6 | 1.0 |
Transcription Factors/metabolism | 21 | 1.0 |
Viral Proteins/biosynthesis | 2 | 6.0 |
Chick Embryo | 3 | 0.0 |
Neuroblastoma | 3 | 1.0 |
Protein-Tyrosine-Phosphatase/antagonists & inhibitors | 5 | 14.0 |
*Signal Transduction/drug effects | 8 | 8.0 |
*Cell Transformation, Neoplastic | 10 | 2.0 |
Oncogene Proteins, Fusion/genetics/*physiology | 2 | 11.0 |
Enzyme Activation/drug effects/physiology | 2 | 3.0 |
src-Family Kinases/*metabolism/physiology | 2 | 66.0 |
Cytoplasm/metabolism | 19 | 2.0 |
MAP Kinase Signaling System | 14 | 5.0 |
Receptors, Erythropoietin/metabolism | 2 | 6.0 |
Recombinant Proteins/metabolism | 29 | 1.0 |
Serine/*metabolism | 15 | 15.0 |
DNA-Binding Proteins/chemistry/*physiology | 4 | 13.0 |
Models, Chemical | 3 | 0.0 |
Protein Conformation | 11 | 0.0 |
Protein Structure, Secondary | 7 | 0.0 |
Trans-Activators/chemistry/*physiology | 4 | 23.0 |
CCAAT-Enhancer-Binding Protein-beta/metabolism | 2 | 20.0 |
DNA, Complementary/metabolism | 6 | 0.0 |
Epidermal Growth Factor/metabolism | 6 | 1.0 |
Inflammation | 6 | 1.0 |
Interleukin-6/metabolism | 22 | 9.0 |
Models, Genetic | 6 | 0.0 |
Peptides/metabolism | 4 | 1.0 |
Receptors, Cytokine/metabolism | 9 | 9.0 |
Cattle | 3 | 0.0 |
Cell Nucleus | 4 | 5.0 |
Cytosol | 2 | 9.0 |
DNA-Binding Proteins/genetics/metabolism | 15 | 3.0 |
Hydrogen Peroxide/*pharmacology | 3 | 5.0 |
Promoter Regions (Genetics)/*genetics | 3 | 0.0 |
Reactive Oxygen Species/*metabolism | 4 | 2.0 |
Sequence Deletion | 12 | 0.0 |
Trans-Activators/genetics/metabolism | 13 | 7.0 |
Transcription Factors/biosynthesis/genetics | 2 | 2.0 |
Protein Processing, Post-Translational/drug effects | 7 | 6.0 |
Antigens, CD34 | 2 | 0.0 |
DNA-Binding Proteins/*metabolism/physiology | 4 | 10.0 |
Hematopoietic Stem Cells/cytology | 2 | 2.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Interleukin-3/pharmacology | 9 | 3.0 |
Trans-Activators/*metabolism/physiology | 4 | 25.0 |
Electrophoresis, Polyacrylamide Gel | 14 | 0.0 |
DNA-Binding Proteins/*drug effects/metabolism | 2 | 25.0 |
Stem Cells/cytology | 2 | 2.0 |
Trans-Activators/*drug effects/metabolism | 3 | 50.0 |
DNA-Binding Proteins/immunology/*metabolism | 2 | 8.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 2 | 1.0 |
Trans-Activators/immunology/*metabolism | 2 | 18.0 |
Antibodies, Monoclonal/pharmacology | 6 | 0.0 |
Apoptosis/physiology | 5 | 1.0 |
Cell Division/drug effects/physiology | 5 | 1.0 |
Enzyme Activation/physiology | 5 | 2.0 |
MAP Kinase Kinase 1 | 7 | 4.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors | 6 | 6.0 |
Cell Differentiation/physiology | 11 | 2.0 |
Head and Neck Neoplasms/*metabolism/pathology | 2 | 9.0 |
Keratinocytes/metabolism | 2 | 1.0 |
Erythropoietin/pharmacology | 4 | 3.0 |
Genes, myc | 5 | 1.0 |
Neoplasm Proteins/*physiology | 5 | 5.0 |
Trans-Activation (Genetics)/drug effects | 9 | 4.0 |
Antigens, CD/*metabolism | 18 | 2.0 |
Breast Neoplasms/*metabolism/pathology | 2 | 1.0 |
Gene Expression Regulation, Neoplastic/drug effects | 8 | 1.0 |
MAP Kinase Signaling System/drug effects | 8 | 8.0 |
Membrane Glycoproteins/*metabolism | 19 | 3.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 3 | 1.0 |
Peptides/pharmacology | 11 | 5.0 |
Receptor, Epidermal Growth Factor/genetics/*metabolism | 2 | 1.0 |
Receptor, erbB-2/metabolism | 5 | 3.0 |
Receptor, erbB-3/metabolism | 3 | 10.0 |
Liver Neoplasms/*metabolism | 2 | 2.0 |
Precancerous Conditions/metabolism | 2 | 12.0 |
Caveolins/metabolism | 3 | 15.0 |
Cholesterol/metabolism | 2 | 0.0 |
Cytokines/*metabolism | 8 | 3.0 |
Detergents/pharmacology | 3 | 2.0 |
Interferon Type II/metabolism | 9 | 3.0 |
Interleukin-6/metabolism/pharmacology | 2 | 20.0 |
Membrane Microdomains/*metabolism | 3 | 6.0 |
Octoxynol/pharmacology | 2 | 3.0 |
Receptors, Interferon/metabolism | 7 | 17.0 |
Subcellular Fractions/metabolism | 3 | 0.0 |
Vanadates/pharmacology | 10 | 7.0 |
*beta-Cyclodextrins | 3 | 7.0 |
Adenocarcinoma/*metabolism/pathology | 2 | 1.0 |
Cell Proliferation | 4 | 2.0 |
English Abstract | 17 | 0.0 |
Lung Neoplasms/*metabolism/pathology | 3 | 4.0 |
Gene Silencing | 2 | 0.0 |
Protein p53/genetics/*physiology | 2 | 5.0 |
Interleukin-6/analysis | 2 | 2.0 |
Acute-Phase Proteins/genetics/metabolism | 3 | 100.0 |
Hepatocyte Growth Factor/*pharmacology | 4 | 2.0 |
Microscopy, Fluorescence | 17 | 0.0 |
Receptors, Tumor Necrosis Factor, Type I | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 3 | 0.0 |
RNA, Messenger/analysis | 15 | 0.0 |
Tissue Inhibitor of Metalloproteinase-1/*genetics | 2 | 12.0 |
*Antigens, Neoplasm | 2 | 1.0 |
*Proteins | 4 | 0.0 |
Tissue Distribution | 3 | 0.0 |
DNA-Binding Proteins/*biosynthesis/genetics | 3 | 3.0 |
Signal Transduction/*drug effects | 39 | 10.0 |
Trans-Activators/*biosynthesis/genetics | 3 | 10.0 |
Age Factors | 2 | 0.0 |
Carrier Proteins/*physiology | 4 | 1.0 |
Energy Metabolism/physiology | 2 | 3.0 |
Leptin/*physiology | 2 | 18.0 |
Rats, Inbred Strains | 5 | 0.0 |
*Receptors, Cell Surface | 10 | 2.0 |
Epithelial Cells/metabolism | 7 | 2.0 |
Interleukin-11/pharmacology | 2 | 8.0 |
Luciferases/genetics | 9 | 2.0 |
RNA, Messenger/genetics | 9 | 0.0 |
Receptors, Retinoic Acid/metabolism | 3 | 3.0 |
Trans-Activation (Genetics)/*physiology | 5 | 4.0 |
Adolescent | 9 | 0.0 |
Autocrine Communication | 2 | 2.0 |
Carrier Proteins/biosynthesis/genetics | 7 | 18.0 |
Cytokines/biosynthesis/genetics | 2 | 3.0 |
Receptors, Interleukin/*physiology | 4 | 16.0 |
Reed-Sternberg Cells/*metabolism/pathology | 2 | 50.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
Multiple Myeloma/*metabolism/pathology | 3 | 15.0 |
Tumor Cells, Cultured/drug effects | 10 | 1.0 |
Adenocarcinoma/genetics/metabolism/*pathology | 2 | 10.0 |
Cycloheximide/pharmacology | 4 | 0.0 |
Enzyme Induction/drug effects | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 7 | 2.0 |
Interleukin-1/*pharmacology | 5 | 1.0 |
Protein Synthesis Inhibitors/pharmacology | 6 | 1.0 |
NF-kappa B/genetics/*metabolism | 3 | 4.0 |
Chromatin/metabolism | 2 | 0.0 |
Cyclin D1/metabolism | 5 | 3.0 |
DNA-Binding Proteins/*chemistry/*metabolism | 4 | 6.0 |
Glutathione Transferase/metabolism | 8 | 1.0 |
Plasmids/metabolism | 21 | 1.0 |
Trans-Activators/*chemistry/*metabolism | 4 | 22.0 |
DNA-Binding Proteins/analysis/*physiology | 2 | 18.0 |
Protein Isoforms/analysis | 2 | 4.0 |
Remission Induction | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
Trans-Activators/analysis/*physiology | 3 | 60.0 |
Treatment Outcome | 7 | 0.0 |
*Erythropoiesis | 2 | 2.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 7 | 4.0 |
Proto-Oncogene Proteins c-myc/genetics | 2 | 3.0 |
Recombinant Fusion Proteins | 4 | 1.0 |
Tyrosine | 7 | 6.0 |
Breast Neoplasms/genetics/metabolism/*pathology | 2 | 5.0 |
Cisplatin/pharmacology | 3 | 1.0 |
Epithelial Cells/metabolism/pathology | 2 | 4.0 |
Mutation/genetics | 5 | 0.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/metabolism | 10 | 15.0 |
Amino Acids/chemistry | 2 | 1.0 |
Anilides/pharmacology | 2 | 7.0 |
Forskolin/pharmacology | 2 | 0.0 |
Prostatic Neoplasms/*metabolism | 4 | 3.0 |
Thiazoles/pharmacology | 2 | 1.0 |
Receptor, Epidermal Growth Factor/drug effects/*physiology | 2 | 13.0 |
Culture Media, Conditioned/pharmacology | 3 | 1.0 |
Herpesvirus 8, Human/*physiology | 3 | 27.0 |
Lymphocyte Activation/*drug effects | 2 | 0.0 |
Viral Proteins/*pharmacology | 3 | 17.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 10 | 3.0 |
Chromones/pharmacology | 5 | 2.0 |
Green Fluorescent Proteins | 10 | 1.0 |
Luminescent Proteins/metabolism | 5 | 1.0 |
Morpholines/pharmacology | 6 | 2.0 |
Proto-Oncogene Proteins/*metabolism | 15 | 1.0 |
Proto-Oncogene Proteins c-jun/*metabolism | 2 | 2.0 |
Tumor Necrosis Factor-alpha/metabolism | 4 | 0.0 |
*Gene Therapy | 2 | 0.0 |
Mice, Inbred DBA | 3 | 0.0 |
Proteins/*genetics/physiology | 2 | 2.0 |
Active Transport, Cell Nucleus | 13 | 5.0 |
Gene Expression Regulation, Viral | 2 | 0.0 |
*Transcription, Genetic | 15 | 0.0 |
*DNA Methylation | 3 | 0.0 |
Growth Inhibitors/pharmacology | 16 | 10.0 |
*Interleukin-6 | 17 | 4.0 |
Lymphokines/pharmacology | 10 | 5.0 |
Organ Specificity | 7 | 0.0 |
Staurosporine/pharmacology | 3 | 1.0 |
B-Lymphocytes/metabolism | 3 | 1.0 |
Recombination, Genetic | 2 | 0.0 |
Viral Matrix Proteins/genetics/*metabolism | 3 | 15.0 |
Cloning, Molecular | 25 | 0.0 |
DNA-Binding Proteins/*genetics | 16 | 0.0 |
*RNA Splicing | 2 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Sequence Alignment | 6 | 0.0 |
Trans-Activators/*genetics | 12 | 3.0 |
Interferon Type II/*pharmacology | 13 | 2.0 |
Interleukin-1/pharmacology | 7 | 1.0 |
Sequence Homology, Amino Acid | 21 | 0.0 |
Gene Expression Regulation, Developmental | 5 | 0.0 |
Repressor Proteins/*genetics | 2 | 0.0 |
Transcription Factors/*genetics | 4 | 0.0 |
Cell Division/genetics/immunology | 2 | 7.0 |
Enzyme Activation/immunology | 10 | 7.0 |
Interferon Type II/antagonists & inhibitors/biosynthesis | 2 | 22.0 |
Milk Proteins/metabolism | 3 | 27.0 |
Signal Transduction/genetics/*immunology | 5 | 5.0 |
Antigens, CD/genetics/physiology | 4 | 25.0 |
Lipopolysaccharides/antagonists & inhibitors/pharmacology | 3 | 14.0 |
Membrane Glycoproteins/genetics/physiology | 3 | 17.0 |
T-Lymphocytes/immunology/metabolism | 4 | 3.0 |
Carrier Proteins/biosynthesis/*metabolism | 2 | 15.0 |
DNA Methylation | 2 | 0.0 |
DNA-Binding Proteins/*pharmacology | 3 | 8.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Trans-Activators/*pharmacology | 3 | 13.0 |
DNA-Binding Proteins/biosynthesis/*metabolism | 5 | 8.0 |
Ovarian Neoplasms/*metabolism/pathology | 2 | 3.0 |
Trans-Activators/biosynthesis/*metabolism | 5 | 33.0 |
Endothelium, Vascular/metabolism | 2 | 0.0 |
*Oxidative Stress | 4 | 1.0 |
*Gene Expression Regulation, Leukemic | 2 | 2.0 |
Leukemia, Myeloid/*genetics/pathology | 2 | 7.0 |
Signal Transduction/genetics | 4 | 1.0 |
Transcription, Genetic/*physiology | 5 | 2.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Protein p53/metabolism | 2 | 0.0 |
Receptor, Epidermal Growth Factor/*metabolism | 6 | 0.0 |
Receptors, Estrogen/metabolism | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 18 | 1.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Enzyme Inhibitors/*pharmacology | 6 | 0.0 |
Ligands | 18 | 0.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors | 2 | 1.0 |
Fibroblasts/cytology/metabolism | 2 | 1.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
Interferon-beta/pharmacology | 5 | 11.0 |
Protein Biosynthesis | 12 | 0.0 |
Proteins/genetics | 9 | 1.0 |
*Ubiquitin-Protein Ligases | 3 | 0.0 |
Interferon Type II/pharmacology | 12 | 2.0 |
Interleukin-10/*antagonists & inhibitors | 2 | 50.0 |
Interleukin-6/*antagonists & inhibitors | 3 | 33.0 |
Protein-Tyrosine Kinase/*physiology | 9 | 6.0 |
Protein-Tyrosine-Phosphatase/genetics/*physiology | 2 | 16.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/metabolism | 3 | 3.0 |
Hematopoietic Stem Cells/cytology/drug effects/*metabolism | 2 | 33.0 |
Isoenzymes/metabolism | 5 | 0.0 |
Oncogene Proteins, Fusion/genetics/*metabolism/pharmacology | 2 | 50.0 |
Phospholipase C/metabolism | 3 | 1.0 |
Protein Kinases/metabolism | 4 | 0.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 2 | 0.0 |
Signal Transduction/*physiology | 46 | 3.0 |
CD4-Positive T-Lymphocytes/*metabolism | 2 | 2.0 |
Interleukin-10/pharmacology | 6 | 8.0 |
Lymphocyte Activation | 10 | 0.0 |
Proto-Oncogene Proteins c-fos/metabolism | 3 | 2.0 |
Proto-Oncogene Proteins c-jun/metabolism | 3 | 2.0 |
Fibroblasts/metabolism | 11 | 1.0 |
Interleukin-4/pharmacology | 7 | 2.0 |
Microscopy, Confocal | 6 | 0.0 |
*Protein-Tyrosine Kinase | 8 | 2.0 |
Antigens, CD/*physiology | 5 | 1.0 |
*JNK Mitogen-Activated Protein Kinases | 2 | 2.0 |
Membrane Glycoproteins/*physiology | 5 | 1.0 |
Apoptosis/*physiology | 7 | 1.0 |
*Brain Injuries/diagnosis/pathology/rehabilitation/therapy | 2 | 22.0 |
Family | 2 | 0.0 |
Amino Acid Motifs | 5 | 0.0 |
Cysteine Endopeptidases/metabolism | 2 | 0.0 |
Cytokines/metabolism | 13 | 3.0 |
Granulocyte Colony-Stimulating Factor/metabolism | 2 | 13.0 |
Growth Inhibitors/*metabolism | 3 | 5.0 |
Lymphokines/*metabolism | 4 | 0.0 |
Multienzyme Complexes/metabolism | 2 | 1.0 |
Peptides/*metabolism | 3 | 1.0 |
Proteasome Endopeptidase Complex | 5 | 0.0 |
RNA/metabolism | 4 | 0.0 |
Receptors, Cytokine/*metabolism | 8 | 9.0 |
Receptors, Interleukin-6/*metabolism | 5 | 33.0 |
Cell Separation | 4 | 0.0 |
*Down-Regulation | 3 | 0.0 |
Interferon-alpha/metabolism | 3 | 13.0 |
Interferon-beta/metabolism | 3 | 15.0 |
Proteins/*metabolism | 13 | 1.0 |
Receptors, Interleukin/metabolism | 4 | 6.0 |
Growth Substances/*pharmacology | 5 | 1.0 |
Macaca mulatta | 2 | 0.0 |
*Neoplasm Proteins | 10 | 1.0 |
Proto-Oncogene Proteins/physiology | 3 | 2.0 |
Receptors, Interleukin-3/physiology | 2 | 66.0 |
Signal Transduction/drug effects/*immunology | 7 | 18.0 |
Thrombopoietin/*physiology | 2 | 10.0 |
CHO Cells/metabolism | 2 | 5.0 |
Cell Transformation, Neoplastic/*metabolism | 3 | 7.0 |
Hamsters | 21 | 0.0 |
Kidney/cytology | 2 | 1.0 |
Liver/cytology | 3 | 4.0 |
*MAP Kinase Kinase Kinase 1 | 7 | 4.0 |
Protein-Serine-Threonine Kinases/metabolism | 12 | 1.0 |
rhoA GTP-Binding Protein/*metabolism | 2 | 3.0 |
src-Family Kinases/metabolism | 8 | 4.0 |
DNA-Binding Proteins/*antagonists & inhibitors/metabolism | 9 | 30.0 |
Drug Antagonism | 2 | 4.0 |
Interleukin-6/*antagonists & inhibitors/pharmacology | 4 | 66.0 |
Protein-Tyrosine-Phosphatase/*physiology | 3 | 11.0 |
Trans-Activators/*antagonists & inhibitors/metabolism | 10 | 50.0 |
Apoptosis/drug effects/*physiology | 7 | 3.0 |
Doxorubicin/pharmacology | 2 | 0.0 |
Interleukin-6/metabolism/*physiology | 2 | 50.0 |
Protein-Serine-Threonine Kinases/*metabolism | 4 | 0.0 |
*Antigens, CD | 3 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
Rats, Wistar | 9 | 0.0 |
Alanine/chemistry | 2 | 2.0 |
Baculoviridae/genetics | 3 | 1.0 |
DNA/*metabolism | 2 | 0.0 |
DNA-Binding Proteins/antagonists & inhibitors/*metabolism | 6 | 22.0 |
Drug Design | 3 | 0.0 |
Growth Substances/metabolism | 2 | 1.0 |
Insects | 4 | 2.0 |
Phosphotyrosine/*chemistry | 2 | 28.0 |
Trans-Activators/antagonists & inhibitors/*metabolism | 6 | 26.0 |
src Homology Domains | 30 | 5.0 |
Electrophoresis, Gel, Two-Dimensional | 2 | 0.0 |
*Gene Expression Profiling | 3 | 0.0 |
Gene Expression Regulation, Leukemic/*drug effects | 2 | 5.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 0.0 |
Tretinoin/*pharmacology | 2 | 0.0 |
Macromolecular Substances | 23 | 1.0 |
Receptors, Interleukin/genetics/*metabolism | 4 | 50.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 11 | 2.0 |
Bone Marrow Cells/metabolism | 3 | 3.0 |
Cytokines/biosynthesis | 4 | 0.0 |
Genetic Vectors | 7 | 0.0 |
Genotype | 3 | 0.0 |
Mitosis | 2 | 0.0 |
Proteins/*physiology | 5 | 2.0 |
Retroviridae/genetics | 4 | 1.0 |
Spleen/cytology | 4 | 2.0 |
Thrombopoietin/*metabolism | 3 | 11.0 |
DNA-Binding Proteins/*chemistry/genetics/*metabolism | 4 | 7.0 |
Kidney | 4 | 1.0 |
Plasmids/genetics | 2 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Trans-Activators/*chemistry/genetics/*metabolism | 4 | 19.0 |
Mitogen-Activated Protein Kinases/*physiology | 3 | 4.0 |
Biological Markers/analysis | 3 | 0.0 |
Prospective Studies | 2 | 0.0 |
Reference Values | 4 | 0.0 |
Sensitivity and Specificity | 5 | 0.0 |
*Drosophila Proteins | 5 | 0.0 |
Serine/chemistry | 4 | 2.0 |
Tyrosine/chemistry | 7 | 5.0 |
Carrier Proteins/genetics/*physiology | 3 | 3.0 |
Cytokines/*physiology | 6 | 3.0 |
Transcription, Genetic/physiology | 4 | 2.0 |
Amino Acid Substitution | 11 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 6 | 3.0 |
Mice, SCID | 4 | 0.0 |
*Oncogenes | 2 | 0.0 |
Stem Cell Factor/pharmacology | 4 | 2.0 |
Signal Transduction/genetics/immunology | 8 | 10.0 |
Gene Expression/drug effects | 6 | 0.0 |
Human Growth Hormone/*pharmacology | 2 | 5.0 |
Liver/drug effects/metabolism | 2 | 2.0 |
Rats, Sprague-Dawley | 14 | 0.0 |
Anticarcinogenic Agents/*pharmacology | 2 | 2.0 |
Signal Transduction/drug effects/physiology | 15 | 6.0 |
Antigens, CD3/immunology | 3 | 1.0 |
Organ Culture Techniques | 3 | 0.0 |
Tumor Necrosis Factor-alpha/genetics | 2 | 0.0 |
Cell Adhesion/drug effects | 5 | 1.0 |
Proteins/genetics/*metabolism | 6 | 1.0 |
Stimulation, Chemical | 4 | 0.0 |
Receptors, Cell Surface/metabolism | 7 | 1.0 |
Carrier Proteins/genetics/*metabolism | 4 | 0.0 |
Granulocyte Colony-Stimulating Factor/*metabolism | 3 | 33.0 |
Monocytes/metabolism | 5 | 1.0 |
Antiviral Agents/pharmacology | 3 | 4.0 |
Gene Expression Regulation/drug effects | 22 | 2.0 |
Interferon-alpha/*pharmacology | 12 | 8.0 |
Culture Media, Conditioned | 2 | 0.0 |
*Drug Resistance, Neoplasm | 2 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/genetics/metabolism | 2 | 3.0 |
Interleukin-6/*physiology | 17 | 20.0 |
rac1 GTP-Binding Protein/*metabolism | 4 | 4.0 |
Antigens, CD/immunology/metabolism/pharmacology | 2 | 100.0 |
DNA-Binding Proteins/drug effects/*metabolism | 6 | 35.0 |
Leukemia/metabolism | 2 | 8.0 |
Membrane Glycoproteins/immunology/metabolism/pharmacology | 2 | 100.0 |
Trans-Activators/drug effects/*metabolism | 6 | 46.0 |
DNA-Binding Proteins/antagonists & inhibitors/metabolism | 6 | 28.0 |
Promoter Regions (Genetics)/immunology | 7 | 10.0 |
Trans-Activators/antagonists & inhibitors/metabolism | 4 | 20.0 |
Up-Regulation/immunology | 5 | 3.0 |
Genes, fos | 5 | 4.0 |
Proto-Oncogene Proteins c-fos/biosynthesis | 2 | 6.0 |
Receptors, Cytokine/physiology | 3 | 11.0 |
Transcription Factors/*physiology | 5 | 1.0 |
Transcription, Genetic/*genetics | 3 | 1.0 |
CHO Cells | 13 | 0.0 |
Receptors, Cell Surface/physiology | 3 | 2.0 |
Cell Division/immunology | 4 | 1.0 |
Growth Inhibitors/*pharmacology | 9 | 4.0 |
Lymphokines/*pharmacology | 8 | 3.0 |
Rats, Inbred F344 | 2 | 0.0 |
Binding Sites/genetics | 8 | 0.0 |
Consensus Sequence | 3 | 0.0 |
DNA/genetics/metabolism | 10 | 2.0 |
Interferon Type I, Recombinant/*pharmacology | 3 | 6.0 |
DNA-Binding Proteins/*chemistry/metabolism | 3 | 4.0 |
Recombinant Fusion Proteins/metabolism | 15 | 0.0 |
Trans-Activators/*chemistry | 2 | 12.0 |
Antibodies, Monoclonal/*pharmacology | 5 | 2.0 |
Culture Media, Serum-Free | 4 | 1.0 |
DNA-Binding Proteins/*antagonists & inhibitors/metabolism/physiology | 2 | 50.0 |
Down-Regulation/drug effects | 5 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis | 2 | 1.0 |
Trans-Activators/*antagonists & inhibitors/metabolism/physiology | 3 | 75.0 |
DNA-Binding Proteins/analysis | 6 | 7.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Protein-Tyrosine Kinase/*analysis | 2 | 6.0 |
Trans-Activators/*analysis | 3 | 12.0 |
Chromosome Mapping | 7 | 0.0 |
Fibroblast Growth Factors/metabolism | 2 | 3.0 |
*Mutation | 4 | 0.0 |
Alanine | 2 | 2.0 |
Antigens, CD/chemistry/*metabolism | 2 | 5.0 |
Carcinoma, Hepatocellular | 19 | 5.0 |
Chimeric Proteins/chemistry/metabolism | 3 | 5.0 |
Granulocyte Colony Stimulating Factor, Recombinant/pharmacology | 2 | 18.0 |
Interferon-gamma, Recombinant/pharmacology | 5 | 3.0 |
Liver Neoplasms | 16 | 5.0 |
Membrane Glycoproteins/chemistry/*metabolism | 2 | 6.0 |
Serine | 3 | 3.0 |
Tetradecanoylphorbol Acetate/pharmacology | 16 | 0.0 |
Protein Subunits | 3 | 0.0 |
Antineoplastic Agents/*therapeutic use | 3 | 0.0 |
Protein Kinase Inhibitors | 4 | 3.0 |
Receptors, Cell Surface/antagonists & inhibitors | 2 | 16.0 |
Breast Neoplasms/enzymology/metabolism/*pathology | 2 | 22.0 |
DNA, Neoplasm/metabolism | 8 | 5.0 |
Insect Proteins | 2 | 50.0 |
Pyridones/pharmacology | 3 | 33.0 |
Pyrimidines/pharmacology | 6 | 5.0 |
Coculture Techniques | 9 | 1.0 |
Lymphocyte Activation/*immunology | 2 | 0.0 |
Receptors, Interleukin-2/biosynthesis | 2 | 1.0 |
Signal Transduction/immunology | 10 | 3.0 |
Dendritic Cells/immunology/metabolism | 2 | 11.0 |
Stromal Cells/physiology | 2 | 3.0 |
Protein Binding/genetics/immunology | 4 | 4.0 |
Carcinoma, Squamous Cell | 2 | 1.0 |
Fibroblasts/cytology/drug effects/physiology | 2 | 18.0 |
Liver/physiology | 2 | 3.0 |
Phosphoproteins/*physiology | 2 | 2.0 |
MAP Kinase Signaling System/drug effects/physiology | 6 | 19.0 |
Cell Differentiation/*physiology | 2 | 0.0 |
DNA-Binding Proteins | 5 | 5.0 |
Trans-Activators | 5 | 12.0 |
Cell Adhesion | 4 | 0.0 |
Carrier Proteins/*genetics | 3 | 0.0 |
Endometrium/cytology/*metabolism | 2 | 6.0 |
Gene Expression Regulation/*drug effects | 10 | 1.0 |
Progesterone/*pharmacology | 2 | 2.0 |
*Hepatectomy | 2 | 5.0 |
Hematopoietic Stem Cells/*metabolism | 2 | 1.0 |
Leukemia, Megakaryocytic, Acute/pathology | 3 | 27.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolism | 3 | 3.0 |
*Cell Division | 2 | 1.0 |
*Cell Survival | 2 | 5.0 |
Leukemia, Myelocytic, Acute/*pathology | 2 | 5.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors/metabolism | 5 | 12.0 |
Tyrphostins/*pharmacology | 4 | 16.0 |
Trans-Activation (Genetics)/*drug effects | 6 | 6.0 |
Up-Regulation/drug effects | 3 | 0.0 |
Transcription Factors/genetics | 4 | 0.0 |
Recurrence | 2 | 0.0 |
Isoenzymes/*metabolism | 3 | 1.0 |
*MAP Kinase Kinase 4 | 2 | 3.0 |
Protein Kinase C/*metabolism | 3 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/metabolism | 4 | 6.0 |
*HIV-1 | 2 | 0.0 |
Leukemia, Myeloid/*pathology | 3 | 5.0 |
Antineoplastic Agents/therapeutic use | 3 | 1.0 |
*Gene Silencing | 2 | 1.0 |
Gene Therapy | 4 | 1.0 |
Colonic Neoplasms/*pathology | 2 | 2.0 |
Neoplasm Invasiveness | 3 | 0.0 |
RNA Interference | 3 | 1.0 |
Up-Regulation/drug effects/physiology | 4 | 8.0 |
DNA-Binding Proteins/chemistry/genetics/*metabolism | 9 | 4.0 |
Interferon-alpha/pharmacology | 5 | 5.0 |
Nuclear Proteins/metabolism | 9 | 1.0 |
Proto-Oncogene Proteins c-myc/metabolism | 3 | 3.0 |
Recombinant Fusion Proteins/chemistry/metabolism | 2 | 1.0 |
Trans-Activators/chemistry/genetics/*metabolism | 9 | 11.0 |
Virus Replication | 2 | 0.0 |
DNA-Binding Proteins/immunology/metabolism | 2 | 10.0 |
Interleukins/immunology/*metabolism | 2 | 100.0 |
Trans-Activators/immunology/metabolism | 2 | 50.0 |
Cell Proliferation/drug effects | 2 | 2.0 |
*Mutation, Missense | 2 | 0.0 |
Piperazines/pharmacology | 4 | 3.0 |
Protein Binding/drug effects/genetics | 2 | 28.0 |
Dihydrotestosterone/pharmacology | 2 | 2.0 |
Protein Binding/drug effects | 9 | 2.0 |
DNA-Binding Proteins/*genetics/metabolism | 10 | 2.0 |
Signal Transduction/*genetics | 5 | 3.0 |
Trans-Activators/*genetics/metabolism | 10 | 8.0 |
Homeostasis | 6 | 1.0 |
Liver/*metabolism | 5 | 1.0 |
Gene Expression/immunology | 2 | 2.0 |
*Receptors, G-Protein-Coupled | 2 | 0.0 |
U937 Cells | 7 | 1.0 |
*Cell Cycle Proteins | 9 | 0.0 |
DNA-Binding Proteins/drug effects/metabolism | 4 | 15.0 |
Gene Expression Regulation, Neoplastic/drug effects/physiology | 2 | 5.0 |
Interleukin-9/*pharmacology | 3 | 37.0 |
Transcription, Genetic/drug effects/physiology | 2 | 5.0 |
Receptors, Fibroblast Growth Factor/genetics/*metabolism | 2 | 5.0 |
Protein-Tyrosine-Phosphatase/metabolism | 12 | 9.0 |
Antiviral Agents/*pharmacology | 6 | 3.0 |
DNA-Binding Proteins/chemistry/*genetics/*metabolism | 2 | 5.0 |
Mutagenesis | 6 | 0.0 |
Trans-Activators/chemistry/*genetics/*metabolism | 2 | 11.0 |
Interferon-alpha/*physiology | 3 | 23.0 |
Protein-Tyrosine Kinase/*immunology | 2 | 13.0 |
T-Lymphocytes/*immunology | 4 | 0.0 |
Hepatocyte Growth Factor/*genetics | 2 | 5.0 |
Cell Survival/physiology | 4 | 2.0 |
*DNA-Binding Proteins | 3 | 0.0 |
Proto-Oncogene Proteins/*physiology | 3 | 1.0 |
Intercellular Adhesion Molecule-1/metabolism | 3 | 1.0 |
Interleukin-8/metabolism | 2 | 1.0 |
B-Lymphocytes/immunology | 2 | 0.0 |
Complement/metabolism | 2 | 2.0 |
Immunity, Natural | 2 | 0.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Bone Marrow Cells | 4 | 0.0 |
Phenotype | 13 | 0.0 |
Receptors, Cytoplasmic and Nuclear/metabolism | 4 | 3.0 |
Serine Endopeptidases/*metabolism | 2 | 2.0 |
CCAAT-Enhancer-Binding Proteins/metabolism | 2 | 4.0 |
DNA-Binding Proteins/genetics/metabolism/*physiology | 4 | 6.0 |
Dexamethasone/pharmacology | 9 | 1.0 |
Glucocorticoids/pharmacology | 3 | 2.0 |
Macrophages/metabolism | 2 | 0.0 |
Trans-Activators/genetics/metabolism/*physiology | 5 | 18.0 |
*Cell Differentiation | 10 | 4.0 |
Cell Nucleus/drug effects/metabolism | 4 | 7.0 |
Muscle, Smooth, Vascular/cytology/drug effects/metabolism | 2 | 28.0 |
Proteins/antagonists & inhibitors/metabolism | 2 | 15.0 |
Androstadienes/pharmacology | 2 | 0.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism | 3 | 3.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/*metabolism | 4 | 5.0 |
Proto-Oncogene Proteins c-fos/genetics | 2 | 3.0 |
Binding, Competitive | 4 | 0.0 |
Enhancer Elements (Genetics)/genetics | 2 | 2.0 |
Interleukin-6/*metabolism/pharmacology | 4 | 22.0 |
Luciferases/genetics/metabolism | 3 | 1.0 |
Regulatory Sequences, Nucleic Acid | 5 | 0.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
1-Phosphatidylinositol 3-Kinase/metabolism/physiology | 2 | 20.0 |
Cell Movement/drug effects | 2 | 0.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism/physiology | 2 | 40.0 |
Phosphoproteins/metabolism | 12 | 1.0 |
Receptor, Epidermal Growth Factor/*physiology | 5 | 3.0 |
Interleukin-10/metabolism | 2 | 3.0 |
Cyclins/*genetics | 2 | 1.0 |
Exons/genetics | 2 | 0.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
Leukemia/*pathology | 2 | 4.0 |
rac1 GTP-Binding Protein/metabolism | 4 | 4.0 |
Antibodies, Blocking/pharmacology | 2 | 2.0 |
Cytoplasm/drug effects/metabolism | 2 | 13.0 |
Protein-Serine-Threonine Kinases/physiology | 2 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/genetics | 2 | 1.0 |
Multiple Myeloma/*metabolism | 3 | 11.0 |
*Proto-Oncogene Proteins c-bcl-2 | 7 | 1.0 |
Gene Expression Regulation, Neoplastic/*physiology | 3 | 1.0 |
Neoplasm Proteins/biosynthesis/genetics/*physiology | 3 | 6.0 |
*Protein Biosynthesis | 3 | 0.0 |
Cysteine Endopeptidases/*metabolism | 3 | 1.0 |
HL-60 Cells | 8 | 1.0 |
Multienzyme Complexes/*metabolism | 3 | 2.0 |
Cell Culture Techniques | 2 | 0.0 |
Interleukin-6/antagonists & inhibitors | 3 | 33.0 |
Receptors, Interleukin-6/physiology | 6 | 66.0 |
Hyperplasia | 2 | 0.0 |
Prostate/metabolism/pathology | 2 | 10.0 |
Receptors, Interleukin/*genetics/metabolism | 2 | 28.0 |
Hepatectomy | 4 | 5.0 |
Interleukin-6/genetics/*metabolism/pharmacology | 2 | 66.0 |
Proto-Oncogene Proteins c-fos/genetics/metabolism | 2 | 7.0 |
Proto-Oncogene Proteins c-jun/genetics/metabolism | 2 | 5.0 |
RNA, Messenger/analysis/genetics | 2 | 0.0 |
*Trans-Activation (Genetics)/drug effects | 3 | 7.0 |
DNA/genetics | 3 | 0.0 |
Protirelin/*genetics | 2 | 66.0 |
Interleukin-13/*pharmacology | 4 | 8.0 |
Interleukin-4/*pharmacology | 6 | 2.0 |
Cell Lineage | 6 | 1.0 |
Enzyme Induction | 4 | 0.0 |
Lymphocyte Activation/drug effects | 3 | 0.0 |
Protein-Serine-Threonine Kinases/*physiology | 2 | 1.0 |
DNA/biosynthesis | 3 | 0.0 |
Insulin-Like Growth Factor I/*pharmacology | 2 | 1.0 |
Interleukin-6/*immunology | 2 | 16.0 |
Exons | 6 | 0.0 |
Genomic Library | 3 | 0.0 |
Introns | 4 | 0.0 |
Estrogen Antagonists/pharmacology | 2 | 2.0 |
Tamoxifen/pharmacology | 2 | 2.0 |
Acute-Phase Proteins/genetics | 3 | 42.0 |
Leupeptins/pharmacology | 2 | 1.0 |
Protein-Serine-Threonine Kinases/genetics/metabolism | 2 | 1.0 |
Immediate-Early Proteins/metabolism | 2 | 6.0 |
Embryo | 4 | 1.0 |
Species Specificity | 2 | 0.0 |
Antineoplastic Agents, Hormonal/*pharmacology | 3 | 5.0 |
Oncogenes | 2 | 0.0 |
Protein Processing, Post-Translational/*drug effects | 6 | 11.0 |
Receptors, Androgen/*metabolism | 4 | 3.0 |
DNA-Binding Proteins/drug effects/genetics/metabolism | 2 | 22.0 |
Hepatocytes/metabolism | 2 | 2.0 |
Trans-Activators/drug effects/genetics/metabolism | 2 | 50.0 |
Chloramphenicol O-Acetyltransferase/metabolism | 2 | 1.0 |
beta-Galactosidase/metabolism | 3 | 1.0 |
Genes, Structural | 2 | 0.0 |
Pregnancy | 6 | 0.0 |
RNA, Neoplasm/metabolism | 2 | 2.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Solubility | 7 | 0.0 |
Receptors, Granulocyte Colony-Stimulating Factor/genetics/metabolism | 2 | 50.0 |
ras Proteins/metabolism | 5 | 3.0 |
MAP Kinase Signaling System/drug effects/*physiology | 2 | 5.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Peptides/*pharmacology | 9 | 4.0 |
Response Elements/immunology | 2 | 12.0 |
Trans-Activation (Genetics)/immunology | 4 | 16.0 |
Interferon-alpha/*metabolism | 3 | 13.0 |
Interleukin-10/*metabolism | 2 | 6.0 |
Mice, Inbred ICR | 4 | 1.0 |
RNA, Messenger | 3 | 0.0 |
B-Lymphocytes/*metabolism | 2 | 1.0 |
Interleukin-13/metabolism | 2 | 12.0 |
Interleukin-4/metabolism | 3 | 3.0 |
Ionomycin/pharmacology | 4 | 1.0 |
T-Lymphocytes/*metabolism | 8 | 2.0 |
Acute-Phase Reaction/genetics | 2 | 40.0 |
Carcinoma, Hepatocellular/pathology | 4 | 8.0 |
Liver Neoplasms/pathology | 4 | 8.0 |
Point Mutation | 10 | 0.0 |
Restriction Mapping | 2 | 0.0 |
HT29 Cells | 4 | 2.0 |
Biological Markers | 2 | 0.0 |
*CDC2-CDC28 Kinases | 2 | 0.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors | 3 | 2.0 |
Growth Inhibitors/metabolism/pharmacology | 2 | 28.0 |
Microtubule-Associated Proteins/*metabolism | 3 | 2.0 |
Peptides/*metabolism/pharmacology | 2 | 20.0 |
Receptors, Interleukin/genetics/metabolism | 2 | 22.0 |
*Tumor Suppressor Proteins | 6 | 0.0 |
Acute-Phase Proteins | 6 | 33.0 |
*RNA Interference | 2 | 5.0 |
Active Transport, Cell Nucleus/physiology | 2 | 3.0 |
Antigens, CD34/biosynthesis | 2 | 2.0 |
Glioma | 2 | 2.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors | 4 | 2.0 |
Prostaglandin-Endoperoxide Synthase/*metabolism | 2 | 3.0 |
Actins/metabolism | 4 | 0.0 |
Phosphoproteins/*metabolism | 4 | 0.0 |
Signal Transduction/drug effects/immunology | 2 | 4.0 |
PC12 Cells | 6 | 1.0 |
Receptor Protein-Tyrosine Kinases/genetics/*metabolism | 3 | 2.0 |
Gene Expression Regulation/*immunology | 2 | 1.0 |
Lipopolysaccharides/*pharmacology | 4 | 0.0 |
Transfection/immunology | 2 | 4.0 |
Lymphocyte Activation/immunology | 2 | 0.0 |
MAP Kinase Signaling System/immunology | 4 | 20.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/*physiology | 2 | 11.0 |
Protein Binding/immunology | 5 | 2.0 |
Cell Cycle/*physiology | 2 | 0.0 |
Cyclins/genetics | 3 | 2.0 |
Immunoglobulin M/*biosynthesis | 2 | 10.0 |
Proto-Oncogene Proteins c-jun/genetics | 5 | 12.0 |
CCAAT-Enhancer-Binding Proteins | 5 | 2.0 |
Phosphoserine | 2 | 50.0 |
Two-Hybrid System Techniques | 10 | 0.0 |
Annexin A5/pharmacology | 2 | 5.0 |
Leukemia, Myeloid/*metabolism | 2 | 6.0 |
RNA, Messenger/analysis/metabolism | 2 | 1.0 |
Carcinoma, Squamous Cell/*metabolism | 4 | 3.0 |
Proto-Oncogene Protein c-met/*biosynthesis | 2 | 10.0 |
CDC2-CDC28 Kinases/metabolism | 2 | 4.0 |
*G1 Phase | 2 | 4.0 |
NIH 3T3 Cells | 7 | 2.0 |
Neoplasms/metabolism | 3 | 3.0 |
Oncogene Proteins/metabolism | 2 | 2.0 |
Retinoblastoma Protein/metabolism | 5 | 1.0 |
*S Phase | 2 | 3.0 |
Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Protein Isoforms/metabolism | 3 | 1.0 |
Concanavalin A/pharmacology | 2 | 0.0 |
Apoptosis/drug effects/physiology | 2 | 2.0 |
Cell Differentiation/drug effects/*physiology | 5 | 7.0 |
Leukemia, Myelocytic, Acute | 4 | 15.0 |
Protein-Tyrosine-Phosphatase/*metabolism | 10 | 7.0 |
Breast Neoplasms/*metabolism | 4 | 1.0 |
Interleukin-6/*blood/genetics | 2 | 33.0 |
Phosphoserine/*metabolism | 3 | 11.0 |
Phosphotyrosine/*metabolism | 2 | 3.0 |
Antigens, CD/genetics/metabolism | 7 | 13.0 |
Membrane Glycoproteins/genetics/metabolism | 7 | 8.0 |
Phosphoserine/metabolism | 5 | 6.0 |
Cricetulus | 3 | 0.0 |
Carcinoma, Squamous Cell/*pathology | 2 | 2.0 |
DNA-Binding Proteins/antagonists & inhibitors/*physiology | 2 | 20.0 |
Trans-Activators/antagonists & inhibitors/*physiology | 2 | 40.0 |
Transplantation, Heterologous | 4 | 0.0 |
*Adaptor Proteins, Signal Transducing | 10 | 0.0 |
*Adaptor Proteins, Vesicular Transport | 5 | 1.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 3 | 0.0 |
*Receptors, Cytokine | 4 | 2.0 |
Carrier Proteins/chemistry/genetics/*metabolism | 2 | 1.0 |
Genes, Reporter/genetics | 2 | 0.0 |
Interleukin-6/antagonists & inhibitors/*pharmacology | 2 | 40.0 |
Jurkat Cells | 6 | 0.0 |
Receptors, Interferon/*metabolism | 2 | 7.0 |
Ribonucleases/metabolism | 2 | 1.0 |
Fibroblast Growth Factor 2/pharmacology | 3 | 1.0 |
Oligodeoxyribonucleotides | 12 | 1.0 |
Oligonucleotides, Antisense/pharmacology | 5 | 1.0 |
Cell Cycle/genetics | 2 | 1.0 |
Genes, Immediate-Early/physiology | 2 | 66.0 |
Growth Substances/physiology | 2 | 1.0 |
Cell Division/genetics | 4 | 1.0 |
*Serine | 2 | 5.0 |
Dose-Response Relationship, Immunologic | 2 | 0.0 |
Receptors, Interleukin/biosynthesis | 4 | 25.0 |
Interleukin-6/biosynthesis | 3 | 1.0 |
NF-kappa B/*metabolism/physiology | 2 | 33.0 |
Trans-Activators/antagonists & inhibitors/*metabolism/physiology | 4 | 100.0 |
Blood Platelets/*physiology | 2 | 1.0 |
Thrombopoietin/*pharmacology | 11 | 11.0 |
Adipocytes/metabolism | 2 | 4.0 |
Nitric-Oxide Synthase/*metabolism | 2 | 2.0 |
Catalytic Domain | 2 | 0.0 |
Transcription Factors/chemistry/*metabolism | 2 | 1.0 |
Brain Neoplasms/*metabolism/pathology | 2 | 4.0 |
Ciliary Neurotrophic Factor/pharmacology | 2 | 20.0 |
Cytokines/*pharmacology | 10 | 2.0 |
Fluorescent Antibody Technique, Indirect | 3 | 0.0 |
Epithelial Cells/pathology/*physiology | 2 | 100.0 |
Genes, src/*physiology | 2 | 25.0 |
Clone Cells | 4 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/genetics/*metabolism | 3 | 5.0 |
Recombinant Fusion Proteins/biosynthesis | 6 | 1.0 |
Acute-Phase Reaction | 3 | 6.0 |
DNA-Binding Proteins/genetics/*immunology | 2 | 14.0 |
Embryonic and Fetal Development | 2 | 0.0 |
Interferon Type II/biosynthesis | 4 | 0.0 |
Trans-Activators/genetics/*immunology | 2 | 50.0 |
Ribosomal Protein S6 Kinases/metabolism | 5 | 7.0 |
DNA/chemistry | 2 | 0.0 |
DNA-Binding Proteins/*metabolism/*physiology | 2 | 9.0 |
G1 Phase | 4 | 1.0 |
G2 Phase | 2 | 1.0 |
RNA, Small Interfering/metabolism | 2 | 1.0 |
Recombinant Proteins/chemistry | 3 | 0.0 |
Morphogenesis | 2 | 0.0 |
Receptors, Interleukin-6/biosynthesis | 3 | 37.0 |
Angiotensin II/*physiology | 2 | 5.0 |
DNA-Binding Proteins/*biosynthesis | 6 | 5.0 |
Trans-Activators/*biosynthesis | 6 | 11.0 |
Cell Cycle Proteins/metabolism | 4 | 1.0 |
NF-kappa B/antagonists & inhibitors/*metabolism | 2 | 3.0 |
Receptors, Interleukin/*metabolism | 4 | 12.0 |
Macrophages/*drug effects/metabolism | 2 | 5.0 |
Gene Expression Regulation/immunology | 3 | 1.0 |
*Growth Inhibitors | 4 | 7.0 |
*Lymphokines | 4 | 9.0 |
Cytokines/*biosynthesis/genetics | 2 | 2.0 |
Biological Transport | 8 | 0.0 |
Cell Transformation, Viral | 4 | 1.0 |
Interleukin-2/*pharmacology | 11 | 4.0 |
*Lymphocyte Activation | 3 | 0.0 |
T-Lymphocytes/*immunology/metabolism | 2 | 1.0 |
Multigene Family | 3 | 0.0 |
Neutrophils/*drug effects/metabolism | 4 | 8.0 |
CD4-Positive T-Lymphocytes/metabolism | 2 | 1.0 |
Cyclosporine/pharmacology | 3 | 1.0 |
Antibodies/pharmacology | 4 | 1.0 |
DNA-Binding Proteins/analysis/*genetics | 2 | 6.0 |
Trans-Activators/analysis/*genetics | 2 | 28.0 |
Nitric Oxide/*metabolism | 2 | 1.0 |
Cell Compartmentation/physiology | 2 | 5.0 |
Acute-Phase Proteins/*genetics | 2 | 15.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/physiology | 3 | 8.0 |
Mitogen-Activated Protein Kinase 1 | 8 | 6.0 |
*Mitogen-Activated Protein Kinases | 10 | 2.0 |
Trans-Activators/analysis | 4 | 13.0 |
src-Family Kinases/*physiology | 5 | 12.0 |
DNA Probes | 2 | 0.0 |
Carrier Proteins/chemistry/*genetics | 2 | 3.0 |
Infant | 3 | 0.0 |
*Point Mutation | 2 | 0.0 |
Receptors, Granulocyte Colony-Stimulating Factor/*genetics | 3 | 50.0 |
Sequence Analysis, DNA | 3 | 0.0 |
1-(5-Isoquinolinesulfonyl)-2-methylpiperazine/pharmacology | 4 | 12.0 |
Haptoglobins/genetics | 2 | 4.0 |
Enterotoxins/*pharmacology | 2 | 3.0 |
Caspases/metabolism | 5 | 0.0 |
Interleukin-6/metabolism/*pharmacology | 3 | 42.0 |
Gene Expression Regulation/drug effects/*physiology | 2 | 2.0 |
Interferons/pharmacology | 3 | 4.0 |
Growth Inhibitors/metabolism | 2 | 6.0 |
Lymphokines/metabolism | 3 | 1.0 |
Stem Cells/cytology/*metabolism | 2 | 5.0 |
Cell Differentiation/drug effects/physiology | 3 | 3.0 |
Gene Transfer Techniques | 4 | 0.0 |
Receptors, Granulocyte Colony-Stimulating Factor/*physiology | 2 | 33.0 |
Conserved Sequence | 7 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
Phylogeny | 2 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 5 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 8 | 2.0 |
Acute-Phase Proteins/*biosynthesis/genetics | 2 | 22.0 |
Liver/drug effects/*metabolism | 2 | 2.0 |
Protein-Tyrosine Kinase/physiology | 7 | 5.0 |
Interleukin-13/*metabolism | 2 | 16.0 |
Pertussis Toxin | 2 | 1.0 |
Virulence Factors, Bordetella/pharmacology | 2 | 1.0 |
Chimeric Proteins/physiology | 2 | 11.0 |
Melanoma/*pathology | 2 | 3.0 |
Protein-Tyrosine-Phosphatase/physiology | 2 | 8.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 7 | 2.0 |
DNA-Binding Proteins/*antagonists & inhibitors | 4 | 23.0 |
Proto-Oncogene Proteins c-bcl-2/*analysis | 2 | 2.0 |
Trans-Activators/*antagonists & inhibitors | 4 | 30.0 |
Hydrogen Peroxide/metabolism | 2 | 1.0 |
Lymphocytes/*metabolism | 2 | 1.0 |
Phytohemagglutinins/pharmacology | 2 | 0.0 |
MAP Kinase Kinase Kinases/metabolism | 2 | 6.0 |
*Neuroblastoma | 2 | 10.0 |
Pertussis Toxin/pharmacology | 2 | 3.0 |
Proto-Oncogene Proteins c-raf/metabolism | 2 | 2.0 |
Leukocytes, Mononuclear/metabolism | 3 | 1.0 |
*Mitogen-Activated Protein Kinase Kinases | 6 | 6.0 |
Calcium/metabolism | 4 | 0.0 |
Carcinogens/pharmacology | 2 | 2.0 |
Protein Kinase C/metabolism | 4 | 0.0 |
Stress, Mechanical | 2 | 0.0 |
Antigens, CD34/analysis | 2 | 0.0 |
Granulocytes/*cytology | 2 | 8.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 5 | 3.0 |
DNA, Complementary | 6 | 0.0 |
Multiple Myeloma/*immunology/pathology | 2 | 11.0 |
Genetic Markers | 2 | 0.0 |
Interleukin-12/*pharmacology | 4 | 8.0 |
Mice, Inbred Strains | 5 | 0.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors/*metabolism | 3 | 50.0 |
Th1 Cells/immunology | 2 | 1.0 |
Receptors, Interleukin-2/*metabolism | 4 | 5.0 |
Sirolimus/pharmacology | 2 | 2.0 |
Ciliary Neurotrophic Factor | 5 | 4.0 |
Nerve Tissue Proteins/*pharmacology | 3 | 3.0 |
Neuroblastoma/metabolism | 2 | 3.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
Interleukin-6/chemistry/*metabolism | 2 | 50.0 |
Protein Array Analysis | 2 | 6.0 |
Protein-Serine-Threonine Kinases/genetics/*metabolism | 2 | 0.0 |
Apoptosis/*genetics | 2 | 0.0 |
Tyrosine/genetics/metabolism | 3 | 15.0 |
DNA-Binding Proteins/*analysis | 2 | 3.0 |
Interleukin-2/*physiology | 4 | 5.0 |
Cyclic AMP/metabolism | 3 | 0.0 |
Leptin | 6 | 5.0 |
Cytoskeleton/*metabolism | 2 | 1.0 |
In Situ Nick-End Labeling | 4 | 0.0 |
Lymphocytes/immunology | 2 | 0.0 |
Alternative Splicing/genetics | 2 | 1.0 |
Protein Isoforms/genetics | 2 | 0.0 |
Apoptosis/*immunology | 2 | 1.0 |
Cell Survival/immunology | 3 | 5.0 |
Butadienes/pharmacology | 3 | 5.0 |
Gene Expression/*drug effects | 3 | 1.0 |
Membrane Glycoproteins/*genetics | 2 | 0.0 |
Nitriles/pharmacology | 3 | 2.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/metabolism | 2 | 2.0 |
Brain/metabolism | 3 | 0.0 |
Enhancer Elements (Genetics) | 3 | 0.0 |
Interleukin-15/pharmacology | 3 | 13.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
Recombinant Proteins | 8 | 1.0 |
Cytoplasm/chemistry | 2 | 1.0 |
Acute-Phase Proteins/*biosynthesis | 2 | 9.0 |
Cyclins/*metabolism | 3 | 1.0 |
Drug Resistance, Neoplasm | 9 | 1.0 |
G1 Phase/drug effects | 2 | 1.0 |
Melanoma/*metabolism/pathology | 2 | 5.0 |
Receptor Protein-Tyrosine Kinases/chemistry/*genetics/*metabolism | 2 | 25.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Interferon-gamma, Recombinant/*pharmacology | 4 | 3.0 |
Injections, Intravenous | 3 | 0.0 |
Herpesvirus 2, Saimiriine/*metabolism | 2 | 50.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/*metabolism | 2 | 5.0 |
Phosphoproteins/genetics/*metabolism | 2 | 1.0 |
T-Lymphocytes | 3 | 1.0 |
Viral Proteins/genetics/*metabolism | 2 | 3.0 |
Angiotensin II/*pharmacology | 3 | 2.0 |
Immunophenotyping | 5 | 0.0 |
Monocytes/*metabolism | 3 | 0.0 |
Receptors, Angiotensin/antagonists & inhibitors | 2 | 4.0 |
Interferon Type II/*metabolism | 3 | 4.0 |
Interleukins/*metabolism | 2 | 15.0 |
Tyrosine/*chemistry | 2 | 15.0 |
Antioxidants/pharmacology | 2 | 1.0 |
Oxidants/pharmacology | 2 | 3.0 |
Protein-Tyrosine Kinase/metabolism/*physiology | 4 | 14.0 |
*Gene Expression Regulation, Developmental | 3 | 0.0 |
Prolactin/*pharmacology | 2 | 2.0 |
Interleukin-6/pharmacology/*physiology | 3 | 27.0 |
Colorectal Neoplasms/*metabolism/pathology | 2 | 4.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
Glucocorticoids/*metabolism | 2 | 8.0 |
Phosphoproteins/genetics | 4 | 3.0 |
Phospholipase C/*metabolism | 2 | 1.0 |
Caco-2 Cells | 2 | 0.0 |
Genes, fos/genetics | 2 | 4.0 |
Mice, Obese | 3 | 6.0 |
RNA, Messenger/drug effects | 2 | 3.0 |
Cytokines/physiology | 2 | 1.0 |
Homeodomain Proteins/*metabolism | 2 | 1.0 |
Receptors, Cell Surface/genetics/*metabolism | 4 | 2.0 |
Phospholipase C/physiology | 2 | 7.0 |
Gene Expression Regulation/*physiology | 3 | 0.0 |
Cell Size | 2 | 0.0 |
Cytokines/chemistry/*physiology | 2 | 33.0 |
Receptors, Cytokine/chemistry/*physiology | 2 | 50.0 |
Interleukin-7/pharmacology | 2 | 4.0 |
Receptors, IgG/metabolism | 2 | 2.0 |
DNA | 3 | 0.0 |
Immunosuppressive Agents/pharmacology | 3 | 1.0 |
Protein p53/physiology | 2 | 2.0 |
Temperature | 2 | 0.0 |
Ultracentrifugation | 2 | 1.0 |
Thrombopoietin/pharmacology | 2 | 3.0 |
Epidermal Growth Factor/*antagonists & inhibitors | 2 | 9.0 |
Erythropoietin/*pharmacology | 5 | 4.0 |
Biopolymers | 2 | 1.0 |
Chromatography, Gel | 2 | 0.0 |
Macrophage Colony-Stimulating Factor/*pharmacology | 3 | 7.0 |
ras Proteins/*metabolism | 2 | 1.0 |
Breast/*metabolism | 2 | 3.0 |
*Gene Expression | 2 | 0.0 |
Genes, src/*genetics | 2 | 20.0 |
RNA, Messenger/drug effects/metabolism | 3 | 2.0 |
Obesity/metabolism | 2 | 4.0 |
Receptors, Cytokine/genetics/metabolism | 2 | 16.0 |
Receptors, Erythropoietin/physiology | 2 | 28.0 |
Carrier Proteins/*metabolism | 6 | 0.0 |
NF-kappa B/*metabolism/*physiology | 2 | 66.0 |
TNF Receptor-Associated Factor 6 | 2 | 1.0 |
Antiviral Agents/metabolism | 2 | 22.0 |
Signal Transduction/drug effects/*genetics | 2 | 20.0 |
Trans-Activators/genetics | 3 | 1.0 |
Gene Targeting | 2 | 0.0 |
Oncogene Protein pp60(v-src)/*metabolism | 2 | 16.0 |
Acute-Phase Proteins/*metabolism | 4 | 7.0 |
DNA-Binding Proteins/*genetics/*metabolism | 2 | 1.0 |
Epithelial Cells/*cytology/metabolism | 2 | 12.0 |
Macrophages/*cytology | 2 | 6.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/biosynthesis | 2 | 9.0 |
Acute-Phase Proteins/biosynthesis | 2 | 15.0 |
Obesity/genetics | 3 | 5.0 |
Neutrophils/*metabolism | 4 | 2.0 |
Hematopoietic Stem Cells/metabolism | 3 | 2.0 |
*Algorithms | 2 | 3.0 |
*Artificial Intelligence | 2 | 18.0 |
*Databases, Factual | 2 | 3.0 |
Feasibility Studies | 2 | 0.0 |
Information Storage and Retrieval/*methods | 2 | 40.0 |
*Natural Language Processing | 2 | 100.0 |
*Periodicals | 2 | 50.0 |
Semantics | 2 | 14.0 |
Software | 2 | 0.0 |
Terminology | 2 | 1.0 |
*Unified Medical Language System | 2 | 66.0 |
Predictive Value of Tests | 2 | 0.0 |
Survival Analysis | 4 | 0.0 |
Drug Resistance, Neoplasm/*genetics | 2 | 2.0 |
Breast Neoplasms/pathology | 4 | 3.0 |
Cell Transformation, Neoplastic/genetics/*metabolism | 2 | 7.0 |
Interleukin-7/*pharmacology | 3 | 7.0 |
Recombinant Proteins/genetics/metabolism | 5 | 0.0 |
Myocardium/*metabolism | 2 | 0.0 |
Cell Differentiation/*drug effects | 2 | 1.0 |
Receptors, Granulocyte Colony-Stimulating Factor/biosynthesis/*physiology | 2 | 100.0 |
T-Lymphocytes/*enzymology | 2 | 3.0 |
Repressor Proteins/metabolism | 6 | 3.0 |
Recombinant Fusion Proteins/genetics/metabolism | 5 | 0.0 |
Receptors, Interleukin/*chemistry/physiology | 2 | 100.0 |
*Trans-Activators | 2 | 0.0 |
Receptors, Interleukin-6 | 6 | 7.0 |
Acute-Phase Proteins/genetics/*metabolism | 2 | 50.0 |
Recombinant Proteins/biosynthesis/pharmacology | 2 | 6.0 |
Cell Nucleus/*enzymology | 2 | 5.0 |
Growth Hormone/*pharmacology | 3 | 4.0 |
Liver/metabolism | 3 | 0.0 |
Interferon-beta/*pharmacology | 4 | 6.0 |
DNA-Binding Proteins/*antagonists & inhibitors/genetics/physiology | 2 | 66.0 |
Trans-Activators/*antagonists & inhibitors/genetics/physiology | 2 | 100.0 |
Flavonoids/*pharmacology | 2 | 2.0 |
Sirolimus | 4 | 9.0 |
Luciferases/biosynthesis | 2 | 2.0 |
Killer Cells, Natural/*immunology | 2 | 0.0 |
T-Lymphocyte Subsets/*immunology/metabolism | 2 | 4.0 |
Interleukin-10/immunology/metabolism | 2 | 25.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Microtubule-Associated Proteins/metabolism | 3 | 2.0 |
Calpain/metabolism | 2 | 8.0 |
Platelet Aggregation | 2 | 1.0 |
Trans-Activators/*chemistry/metabolism | 2 | 13.0 |
Peptide Mapping | 2 | 0.0 |
Liver/cytology/drug effects/*metabolism | 2 | 10.0 |
Polyenes/pharmacology | 3 | 11.0 |
Antigens, CD/immunology | 2 | 0.0 |
B-Lymphocytes/*immunology | 3 | 0.0 |
Membrane Glycoproteins/immunology | 2 | 1.0 |
Antigens, CD/biosynthesis/*physiology | 2 | 6.0 |
Chemokines/*biosynthesis | 2 | 6.0 |
Trans-Activators/drug effects/metabolism | 3 | 14.0 |
Interleukin-12/*metabolism | 2 | 15.0 |
Receptor, Epidermal Growth Factor/genetics/metabolism | 2 | 3.0 |
Receptors, Interleukin/chemistry/*metabolism | 2 | 22.0 |
Wound Healing | 3 | 2.0 |
1-Phosphatidylinositol 3-Kinase/physiology | 4 | 3.0 |
Cell Survival/*physiology | 2 | 3.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
Microtubule-Associated Proteins/*genetics | 2 | 3.0 |
Binding Sites/physiology | 2 | 1.0 |
1-Phosphatidylinositol 3-Kinase | 2 | 1.0 |
Molecular Weight | 3 | 0.0 |
DNA-Binding Proteins/antagonists & inhibitors/genetics/*physiology | 2 | 28.0 |
Trans-Activators/antagonists & inhibitors/genetics/*physiology | 2 | 28.0 |
Intestinal Mucosa/*metabolism | 3 | 3.0 |
Oligonucleotide Probes | 2 | 0.0 |
Receptors, Interleukin-4 | 3 | 4.0 |
Dactinomycin/pharmacology | 4 | 1.0 |
Molecular Structure | 3 | 0.0 |
Prolactin/metabolism | 2 | 3.0 |
DNA, Neoplasm/genetics/metabolism | 2 | 2.0 |
Cell Division/*physiology | 4 | 2.0 |
Viral Proteins/metabolism | 2 | 2.0 |
Ciliary Neurotrophic Factor/metabolism | 3 | 75.0 |
Dogs | 2 | 0.0 |
Receptor, Ciliary Neurotrophic Factor/metabolism | 2 | 66.0 |
Genes, Immediate-Early | 2 | 3.0 |
Interferon Type II | 2 | 11.0 |
Chromatin Immunoprecipitation | 2 | 5.0 |
Doxycycline/pharmacology | 2 | 3.0 |
Heat | 2 | 0.0 |
Chickens | 2 | 0.0 |
Embryo/*cytology | 2 | 6.0 |
Escherichia coli/metabolism | 3 | 1.0 |
Recombinant Proteins/biosynthesis/metabolism/pharmacology | 2 | 16.0 |
Sheep | 2 | 0.0 |
Phosphoproteins/isolation & purification/metabolism | 2 | 5.0 |
Fusion Proteins, bcr-abl/*metabolism | 2 | 5.0 |
Interleukin-6/antagonists & inhibitors/*physiology | 2 | 66.0 |
Receptors, Interleukin-6/antagonists & inhibitors | 2 | 66.0 |
Aspirin/pharmacology | 2 | 3.0 |
Epinephrine/pharmacology | 2 | 2.0 |
Platelet Aggregation Inhibitors/pharmacology | 2 | 3.0 |
Antigens, CD/genetics/*metabolism | 3 | 3.0 |
Membrane Glycoproteins/genetics/*metabolism | 3 | 1.0 |
Protein Structure, Tertiary/genetics | 2 | 0.0 |
Hydrogen Bonding | 2 | 1.0 |
Inhibitory Concentration 50 | 3 | 1.0 |
Peptides/chemistry | 3 | 0.0 |
DNA Mutational Analysis | 4 | 0.0 |
Arthritis, Rheumatoid/*immunology | 2 | 0.0 |
Cytokines/genetics/*metabolism | 2 | 5.0 |
Haplorhini | 2 | 0.0 |
Interleukin-15 | 2 | 22.0 |
Leptin/chemistry/*metabolism | 2 | 50.0 |
Receptors, Cell Surface/*metabolism | 4 | 0.0 |
Colony-Forming Units Assay | 2 | 0.0 |
Repressor Proteins/*metabolism | 3 | 1.0 |
Tyrosine/analogs & derivatives/analysis | 2 | 5.0 |
Membrane Glycoproteins/*pharmacology | 2 | 2.0 |
T-Lymphocytes/drug effects/immunology/*metabolism | 2 | 8.0 |
Leukemia, Megakaryocytic, Acute | 2 | 20.0 |
Tyrosine/analogs & derivatives/metabolism | 4 | 3.0 |
1-(5-Isoquinolinesulfonyl)-2-methylpiperazine | 2 | 3.0 |
Piperazines/*pharmacology | 2 | 3.0 |
Protein-Tyrosine Kinase/genetics/metabolism | 3 | 4.0 |
Receptors, Immunologic/metabolism | 3 | 1.0 |
Granulocytes/cytology | 2 | 4.0 |
Monocytes/cytology | 2 | 1.0 |
Proteins | 2 | 3.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
Hepatocytes/*drug effects/*metabolism | 2 | 40.0 |
Interleukin-6/immunology/metabolism | 2 | 40.0 |
Paclitaxel/pharmacology | 2 | 2.0 |
Protein-Tyrosine Kinase/genetics/*metabolism | 4 | 2.0 |
Antigens, CD45/*physiology | 2 | 16.0 |
Cell Line, Tumor/drug effects/metabolism | 2 | 16.0 |
Receptors, Cell Surface/*physiology | 2 | 0.0 |
Repressor Proteins/*physiology | 2 | 1.0 |
Oncogenes/physiology | 2 | 12.0 |
Cyclin D1/biosynthesis | 3 | 7.0 |
Promoter Regions (Genetics)/physiology | 3 | 1.0 |
Chromans/pharmacology | 2 | 8.0 |
Immunosorbent Techniques | 2 | 0.0 |
Epidermal Growth Factor/*metabolism | 2 | 0.0 |
Carcinoma, Squamous Cell/pathology | 2 | 4.0 |
Transforming Growth Factor alpha/metabolism | 2 | 2.0 |
Receptors, Cell Surface/genetics/physiology | 2 | 11.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
*Genes, fos | 2 | 3.0 |
Transcription Factor AP-1/genetics/metabolism | 2 | 9.0 |
Hepatocyte Growth Factor/metabolism | 3 | 5.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 3 | 0.0 |
Liver Regeneration/*physiology | 3 | 12.0 |
S Phase | 2 | 0.0 |
Precipitin Tests/methods | 2 | 5.0 |
Killer Cells, Natural/metabolism | 2 | 3.0 |
Insulin-Like Growth Factor I/pharmacology | 2 | 1.0 |
Neurosecretory Systems/*physiology | 2 | 7.0 |
Cytokines/metabolism/pharmacology | 2 | 11.0 |
Cell Communication | 2 | 0.0 |
Leptin/metabolism | 3 | 17.0 |
Neoplasm Proteins/*biosynthesis | 2 | 2.0 |
Protein Isoforms | 2 | 0.0 |
Protein-Tyrosine-Phosphatase/genetics/*metabolism | 2 | 4.0 |
Membrane Glycoproteins/genetics/*physiology | 2 | 2.0 |
DNA, Neoplasm/genetics | 4 | 0.0 |
Glycosylation | 2 | 0.0 |
Interferons/metabolism | 2 | 8.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Threonine/chemistry | 2 | 2.0 |
Proteins/chemistry/*physiology | 2 | 9.0 |
Esophageal Neoplasms/*pathology | 2 | 11.0 |
Leptin/*metabolism | 4 | 22.0 |
Heat-Shock Proteins 90/metabolism | 2 | 6.0 |
Oxidation-Reduction | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
History, 20th Century | 2 | 1.0 |
History, 21st Century | 2 | 5.0 |
Cullin Proteins/chemistry/*physiology | 2 | 20.0 |
Ubiquitin/physiology | 2 | 18.0 |
Ubiquitin-Protein Ligases/chemistry/*physiology | 2 | 16.0 |
Acanthamoeba/*drug effects/*growth & development | 2 | 28.0 |
Amebiasis/*drug therapy/parasitology/pathology | 2 | 28.0 |
Amebicides/*pharmacology | 2 | 25.0 |
Chlorpromazine/*pharmacology | 2 | 9.0 |
Cornea/cytology/parasitology/pathology | 2 | 28.0 |
Miocamycin/*analogs & derivatives/*pharmacology | 2 | 28.0 |
Heat-Shock Proteins/metabolism | 3 | 5.0 |
Granulocyte Colony-Stimulating Factor/chemistry/*pharmacology | 2 | 100.0 |
Disease-Free Survival | 2 | 0.0 |
Active Transport, Cell Nucleus/drug effects | 2 | 5.0 |
DNA-Binding Proteins/*antagonists & inhibitors/chemistry/metabolism | 2 | 50.0 |
Trans-Activators/*antagonists & inhibitors/chemistry/metabolism | 2 | 66.0 |
Fluorescence Resonance Energy Transfer | 2 | 4.0 |
Catechin/*analogs & derivatives/*pharmacology | 2 | 8.0 |
Protein Isoprenylation/drug effects | 2 | 11.0 |
Proto-Oncogene Protein p21(ras)/metabolism | 2 | 2.0 |
Neurons/*drug effects/metabolism | 2 | 10.0 |
*Drug Design | 2 | 2.0 |
Protein Subunits/genetics/*metabolism | 2 | 11.0 |
Luminescent Proteins/genetics | 3 | 1.0 |
Adenoviridae/genetics | 2 | 0.0 |
Chronic Disease | 3 | 0.0 |
Blotting, Western/methods | 2 | 1.0 |
DNA-Binding Proteins/antagonists & inhibitors/*metabolism/physiology | 2 | 50.0 |
Fibroblasts/cytology/physiology | 2 | 2.0 |
Blastocyst/cytology/*metabolism | 2 | 66.0 |
Cell Differentiation/*genetics | 2 | 2.0 |
Gene Expression Regulation, Developmental/genetics | 2 | 2.0 |
Homeodomain Proteins/genetics/*isolation & purification | 2 | 100.0 |
Mice/*embryology/genetics/metabolism | 2 | 100.0 |
Pluripotent Stem Cells/cytology/*metabolism | 2 | 50.0 |
Base Sequence/genetics | 2 | 0.0 |
Interferon Type II/*biosynthesis/genetics | 2 | 9.0 |
Endothelium, Vascular/cytology/metabolism | 2 | 1.0 |
Enzyme Inhibitors/metabolism | 3 | 1.0 |
Cell Fractionation | 4 | 1.0 |
Estradiol/metabolism | 2 | 2.0 |
Estrogen Receptor alpha | 2 | 0.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 2 | 1.0 |
Risk Assessment | 2 | 0.0 |
Thiazoles/*pharmacology | 2 | 3.0 |
Gene Expression Regulation/drug effects/physiology | 2 | 3.0 |
NF-kappa B/*physiology | 2 | 2.0 |
Receptors, Cell Surface/genetics/metabolism | 2 | 3.0 |
Carcinogenicity Tests | 2 | 2.0 |
Hematopoietic Stem Cell Mobilization | 2 | 2.0 |
Response Elements/physiology | 2 | 6.0 |
Proteins/*genetics/metabolism | 2 | 0.0 |
Cysteine Proteinase Inhibitors/metabolism | 2 | 14.0 |
Quinones/metabolism | 2 | 14.0 |
*Thiazolidinediones | 2 | 2.0 |
Trans-Activators/drug effects/genetics/*metabolism | 2 | 16.0 |
